Blog
RSS FeedPosted by Michael Wonder on 16 Oct 2017
Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system
4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...
Posted by Michael Wonder on 13 Oct 2017
Hundreds of patients to have access to head and neck cancer drug after new deal, says NICE
13 October 2017 - Nivolumab is recommended for use within the Cancer Drugs Fund for some patients with head and neck ...
Posted by Michael Wonder on 12 Oct 2017
New treatment option for people with gastro-intestinal cancer
12 October 2017 - More people will be able to receive regorafenib now that NICE has said it should move out ...
Posted by Michael Wonder on 11 Oct 2017
Xeljanz receives positive reimbursement decision in England
11 October 2017 - The UK’s HTA body NICE has provided final guidance recommending Xeljanz (tofacitinib citrate) as a treatment ...
Posted by Michael Wonder on 09 Oct 2017
Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation
9 October 2017 - Healthcare systems depend on the availability of new antibiotics. ...
Posted by Michael Wonder on 07 Oct 2017
Leukaemia patients to get access to AbbVie’s Venclyxto via Cancer Drugs Fund
5 October 2017 - AbbVie has struck a deal with NICE to make its leukaemia drug Venclyxto available through the ...
Posted by Michael Wonder on 05 Oct 2017
ABPI update on application for judicial review
4 October 2017 - The ABPI have issued a statement regarding its application for judicial review versus NICE. ...
Posted by Michael Wonder on 30 Sep 2017
Improved access? The reality of the PPRS
29 September 2017 - In the third in her series of five articles, Leela Barham considers the extent to which ...
Posted by Michael Wonder on 29 Sep 2017
Price deal sees NICE back Imbruvica for one indication but not another
28 September 2017 - The UK’s NICE has recommended Imbruvica (ibrutinib), within its marketing authorisation, for use on the Cancer ...
Posted by Michael Wonder on 28 Sep 2017
NICE knocks-back Janssen's Imbruvica in Mantle cell lymphoma
28 September 2017 - Janssen has received mixed news from the UK’s cost-effectiveness watchdog for its cancer drug Imbruvica (ibrutinib). ...
Posted by Michael Wonder on 27 Sep 2017
New advance value framework offered as a decision-support tool for reimbursement
25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...
Posted by Michael Wonder on 26 Sep 2017
Drugs watchdog NICE attacks pharmaceutical industry in pricing dispute
25 September 2017 - Industry expert’s evidence is not independent, NICE argues. ...
Posted by Michael Wonder on 25 Sep 2017
NICE nod for new Eylea indication
22 September 2017 - NICE has issued a final positive recommendation for Bayer’s Eylea as a treatment for adults for ...
Posted by Michael Wonder on 20 Sep 2017
Nivolumab now available for lung cancer after company offers NICE new CDF deal
20 September 2017 - Around 1,300 lung cancer patients will receive nivolumab as part of a CDF deal put forward ...
Posted by Michael Wonder on 18 Sep 2017
NICE rejects first-line use of Roche’s Gazyvaro
18 September 2017 - The National Institute for Health and Care Excellence has turned down first-line use of Roche’s Gazyvaro ...